ABSTRACT
Introduction Diabetes mellitus (DM) in Bahia, Brazil, is a critical public health issue, intensified by socioeconomic inequalities. Years of life lost (YLL) highlight healthcare access gaps, impacting vulnerable populations. Enhanced healthcare infrastructure, education, and policy changes are essential to reduce DM morbidity and premature mortality.
Objective To quantify the societal burden of DM in Bahia, Brazil, by estimating YLL due to premature mortality between 2000 and 2023.
Method This study uses a quantitative epidemiological approach to estimate YLL due to DM in Bahia, Brazil (2000–2023). Mortality data from the Mortality Information System (SIM) and demographic projections from IBGE were analyzed. YLL was calculated by multiplying deaths by remaining life expectancy (using GBD 2019 reference tables), stratified by age and sex. Statistical analysis employed PSPP, Excel, and Python, with results presented as rates per 100,000 population. Socioeconomic and healthcare factors were contextualized using government reports and academic literature.
Results The study analyzed YLL due to DM in Bahia (2000–2023), revealing an upward trend, peaking in 2020 (422.6/100,000), likely exacerbated by COVID-19. Males showed higher premature mortality than females (34.9 vs. 29.8/100,000 in 2020). Economic losses reached ~41 million BRL (2020–2022). Rising YLL reflects growing DM burden, with socioeconomic impacts including lost productivity and household instability. Gender disparities suggest differences in healthcare access, biological susceptibility, or lifestyle factors, necessitating targeted interventions.
Conclusion Bahia faces rising diabetes-related premature deaths, worsening post-2015 and spiking during COVID-19. Men show higher mortality, with severe socioeconomic impacts, requiring urgent public health and economic strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
